GSK's Tafenoquine Faces Questions Over Review Pathways At US FDA Panel
Executive Summary
Advisory committee questions about malaria drug’s breakthrough therapy and orphan drug designations reflect lingering confusion about how agency’s various regulatory pathways impact product development and approval.
You may also be interested in...
GSK Moves Closer To Priority Review Voucher As US Panel Backs Malaria Drug Tafenoquine
GlaxoSmithKline's user fee date is July 22, four days before advisory committee review of 60 Degrees’ separate application for the compound.
GSK’s Malaria Drug Tafenoquine Heads To US FDA Panel Review With Agency Backing
Approval could bring GlaxoSmithKline a tropical disease priority review voucher.
“Breakthrough” Designation: FDA Clarifies How To Get It – And How It Can Be Lost
“Preliminary clinical evidence” should demonstrate substantial improvement in effectiveness or safety over available therapies but likely will not be sufficient to support approval, final guidance explains.